Featured by Life Sciences Review Europe
EVis Bioscience has been featured by Life Sciences Review Europe for its innovative approach to RNA delivery and targeted gene therapy. The editorial highlights the company’s differentiated technological strategy and its potential impact on next-generation therapeutic development.
At the core of the feature is EVis Bioscience’s hybrid RNA delivery platform, which integrates stabilized extracellular vesicles (EVs) with engineered lipid-based components. This approach is designed to combine biological compatibility with manufacturing control, addressing critical limitations of conventional viral and synthetic delivery systems.
A Hybrid Platform with Translational Focus
The company’s technology enables:
- High-efficiency RNA loading
- Targeted tissue delivery through biologically aligned carriers
- Improved safety profile compared to traditional viral vectors
- Scalable production compatible with clinical development
By operating under physiological conditions and preserving vesicle integrity, the platform aims to enhance stability, reduce off-target effects, and enable repeat dosing strategies — key requirements for rare genetic disease applications.
As an ETH Zurich spin-off, EVis Bioscience continues to expand its scientific validation and collaborative network, positioning itself as a next-generation RNA therapeutics enabler within the European biotech ecosystem.
👉 Read the full feature on Life Sciences Review Europe
